AMA grants additional CPT® Code for ProtegaTM

Verici Dx plc

("Verici Dx" or the "Company")

American Medical Association grants Verici Dx additional CPT® Code for Protega^TM

CPT Codes facilitate reimbursement and represent first milestone on pathway to commercialisation

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces it has been granted a CPT® Proprietary Laboratory Analyses ("PLA") code1,2 for its Protega test by the American Medical Association ("AMA"). The new code, X257U, has been approved and published by the AMA Editorial Panel and are scheduled to become effective on October 1, 2026.

Patti Connolly, COO of Verici Dx, said: "We were delighted with the AMA's decision as CPT® codes are fundamental in the commercialisation of Protega."

Reimbursement in the US is comprised of three components: code, price and coverage. CPT® codes offer health care professionals a uniform language for coding medical services and procedures, and the CPT® PLA code allows clinical laboratories to more specifically identify their tests when billing Medicare and commercial insurers. The successful granting of a CPT® code marks the first step on the path for commercial reimbursement.

Notes:

1.  Current Procedural Terminology (CPT) codes are medical codes that are used to report medical, surgical, and diagnostic procedures and services to entities such as physicians, health insurance companies and accreditation organizations.  CPT codes are also used for administrative management purposes such as claims processing and developing guidelines for medical care review.

2.    PLA codes are CPT codes including a corresponding descriptor for laboratories or manufacturers that want to identify their test more specifically.

Verici Dx

Verici Dx plc (AIM: VRCI) is a precision diagnostics company transforming care for transplant patients. The company combines multiomic analysis with proprietary artificial intelligence to deliver predictive, actionable, data-driven intelligence that reflects the complexity and heterogeneity of transplant patients, enabling clinicians to optimise therapy, guide biopsy decisions, and stratify risk with greater confidence.

Operating at the intersection of laboratory and data science, Verici Dx develops complex models that answer the clinical questions that matter most with unrivaled clarity and precision. All tests are built to rigorous scientific standards, validated across inclusive, and real-world patient populations to ensure clinical relevance and reliability. Verici Dx's lead product, Tutivia™, is a post-kidney transplant test focused on early detection of acute rejection.

The company is UK headquartered in Cardiff for the UK, and in Franklin, Tennessee for the U.S. For more